Wet macular degeneration

This trial tests whether an experimental drug called ONS-5010 (a form of bevacizumab) works as well as an approved drug, Lucentis, for treating wet age-related macular degeneration (AMD). Wet AMD causes rapid vision loss due to abnormal blood vessels leaking fluid in the eye. Abo…

This early-phase study tested a new drug called ASKG712 in 56 people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The drug is injected into the eye and works by blocking two proteins that fuel abnormal blood vessel growth. The main goals were t…

This study tested a pre-filled syringe containing a high dose (8 mg) of the drug aflibercept for two eye conditions: diabetic macular edema and wet age-related macular degeneration. The main goal was to see if retina specialists could prepare and inject the drug easily and safely…

This early-phase trial tested NT-101 eye drops in 20 people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The study aimed to check safety and see if the drops could reduce fluid buildup and improve vision. Participants received either a low or h…

This study tested whether a pre-filled syringe of the medicine SB11 (a biosimilar to ranibizumab) is easy for eye doctors to use. Thirty adults with wet age-related macular degeneration, macular edema from retinal vein occlusion, or myopic choroidal neovascularization received on…

This study tested three different doses of SYL1801 eye drops in 99 people with wet age-related macular degeneration (AMD). The goal was to see if the drops are safe and can improve or maintain vision. Participants used the drops for a set period, and their vision was measured aft…

This early-stage trial tested a gene therapy called EXG102-031 in 12 people with wet age-related macular degeneration (nAMD), a condition where abnormal blood vessels damage central vision. The therapy was injected into the eye to block these vessels. The main goal was to check s…

This study looked at 742 people newly diagnosed with wet age-related macular degeneration (nAMD) who received 3 monthly injections of faricimab (Vabysmo) instead of the usual 4. The goal was to see how long the effect lasted before another injection was needed. Researchers tracke…

This early-phase trial tested an investigational eye injection called OLN324 in 164 adults with either wet age-related macular degeneration (AMD) or diabetic macular edema (DME). The main goal was to check safety and how the drug moves in the body, with a preliminary look at whet…

This study tested a new medicine called JL14002 against a standard treatment (ranibizumab) for wet age-related macular degeneration, a leading cause of vision loss. 443 adults aged 50-80 with active disease received injections into the eye. The main goal was to see if JL14002 imp…

This study tested a new medication, LUBT010, against the standard drug Lucentis for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. Six hundred participants received monthly injections into the eye for one year. The goal was to see if LUBT0…

This early-stage trial tested a new drug called PMC-403 in 17 people with wet age-related macular degeneration (nAMD), a leading cause of vision loss. The drug is injected directly into the eye. The main goal was to check safety and find the best dose for future studies. The tria…

This early-stage study tested a new drug called OLX10212 in 21 people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The main goal was to see if the eye injections are safe and tolerable. Researchers also looked for early signs that the drug migh…

This study tested a new medicine called BAT5906 against a standard treatment (Lucentis) for wet age-related macular degeneration, a condition that can cause rapid vision loss. 488 adults aged 50-85 with active disease received either BAT5906 or Lucentis injections into the eye. T…

This study tested whether adding a light-based treatment (photodynamic therapy) to the standard drug ranibizumab could reduce the number of eye injections needed for wet macular degeneration. Sixty adults over age 50 with the condition took part. The goal was to see if the combin…

This study tested a new drug called EYE103, given as an injection into the eye, for people with diabetic macular edema (DME) or wet age-related macular degeneration (NVAMD). The trial had two parts: first, checking safety at increasing doses in about 12 people, then comparing two…

This study tested a new drug called FYB203, which is a biosimilar (a close copy) of the existing medication Eylea, for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The trial involved 434 participants and compared how well FYB203 worked v…

This completed Phase 4 study tested how much of the drug aflibercept gets into the bloodstream when a high dose (8 mg) is injected into both eyes of adults with diabetic macular edema or wet age-related macular degeneration. Fifty-one participants received the injections and had …

This study looked at the long-term safety of faricimab, a drug injected into the eye, for people with wet age-related macular degeneration (AMD). Over 1,000 participants who had completed earlier studies received faricimab at personalized intervals. The main goal was to track sid…

This phase 2 trial tested a new drug called EYP-1901, given as an eye injection, for people with wet age-related macular degeneration (AMD). The goal was to see if it works as well as the standard treatment, aflibercept (Eylea), but with fewer injections. 161 participants receive…

This study compared two different dosing schedules of brolucizumab (Beovu) in 52 people with wet age-related macular degeneration (AMD) who had not responded well to previous treatment. Participants received the drug as an eye injection either on a fixed schedule or with adjustme…

This phase 2 trial tested carbidopa-levodopa (Sinemet), a drug usually used for Parkinson's disease, in 20 people with wet age-related macular degeneration (AMD). The goal was to see if the drug is safe and can improve vision or reduce retinal swelling. Participants took the pill…

This phase 2 trial tested carbidopa-levodopa, a drug used for Parkinson's disease, in 35 people with wet age-related macular degeneration (AMD). The goal was to see if the drug could improve vision and reduce the need for standard anti-VEGF eye injections. Participants took the o…

This phase 3 trial tested whether a new drug called ABP 938 works as well as the standard treatment Eylea for wet age-related macular degeneration (AMD), a leading cause of vision loss. 576 adults aged 50 and older with wet AMD received injections of either ABP 938 or Eylea every…

This study tests a drug called carbidopa-levodopa (Sinemet), typically used for Parkinson's disease, in people with wet age-related macular degeneration (AMD). It is a 9-month extension for 35 participants who completed an earlier study. The goal is to see if the drug can help ma…

This early-stage trial tested the safety of SCAI-005, an eye drop containing axitinib, in 48 healthy Korean adults. The goal was to see if the drug is safe and how it behaves in the body when given as single or multiple doses. It is a first step toward a potential needle-free tre…

This study tested an artificial intelligence (AI) system called Retina4IRD that helps doctors diagnose inherited retinal diseases, which are rare eye conditions that can cause vision loss. The AI looks at eye images and patient information to suggest which gene might be causing t…

This study tested a new device called CRYSTALSIGHT that uses eye-tracking and artificial intelligence to monitor macular diseases like age-related macular degeneration and diabetic retinopathy. Twenty participants used the device at home to see if it could accurately track eye mo…

This study tested a new imaging device called OCT angiography (OCTA) that takes 3D pictures of blood vessels in the back of the eye without needing dye injections. Researchers compared OCTA images to standard dye-based imaging in 88 people with retinal blood vessel problems or no…

This study tested whether injections of aflibercept (Eylea) into the eye could prevent the development of wet age-related macular degeneration (AMD) in people at high risk. 128 participants with early signs of AMD in one eye and wet AMD in the other eye received either Eylea or a…

This study tested whether playing slow tempo music before and during an eye injection (intravitreal injection) can reduce anxiety and pain. 144 adults took part, with half listening to music and the other half receiving standard care. Researchers measured anxiety using saliva tes…

This trial tests a new device called P200TxE that takes detailed images of the back of the eye. Researchers want to see how well it captures images in people with retinal diseases like glaucoma or macular degeneration. The study involves adults aged 22 and older who have been dia…

This study tested whether artificial intelligence (AI) can help doctors detect retinal diseases from ultra-widefield eye images. 462 images were read by four eye doctors with different experience levels, both with and without AI assistance. The goal was to see if AI improves accu…

This study tested whether doctors could safely and correctly use a new prefilled syringe (SCD411) for eye injections. It included 33 adults with wet age-related macular degeneration, retinal vein occlusion, diabetic macular edema, or diabetic retinopathy. The main goal was to see…

This study looked at how much of a burden patients feel from repeated anti-VEGF eye injections for three different eye diseases: wet age-related macular degeneration, retinal vein occlusion, and diabetic macular edema. Researchers surveyed 393 patients about their treatment burde…

This study looked at proteins in the eye fluid of 100 people with wet age-related macular degeneration (AMD). The goal was to measure certain growth factors that might explain why about 37% of patients do not respond well to standard anti-VEGF injections. Researchers collected a …

This study tested a new type of camera that can see individual cells in the retina, which standard clinical cameras cannot do. Five people with retinal disease (inherited degeneration or toxicity) had their eyes scanned with the device. The goal was to compare image quality and o…

This study measured the thickness of the conjunctiva and Tenon's capsule (outer eye layers) in 736 people with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME), and in healthy volunteers of similar age. Researchers used a special eye scanner (SD…

This study looked at 91 people with a type of bleeding in the eye caused by age-related macular degeneration (AMD). It compared two treatments: surgery followed by anti-VEGF injections, or a gas injection followed by anti-VEGF injections. The goal was to see which approach helps …

This study looked at 30 patients with a type of age-related macular degeneration (AMD) to see how treatment affects the barrier between blood and eye fluid. Researchers measured protein levels in the eye fluid before and during anti-angiogenic therapy. The goal was to better unde…

This study collected information from nearly 1,000 people in France with inherited retinal diseases (IRDs) to better understand the genetics behind these conditions. Researchers looked at genetic test results and disease types to help build a national registry. The goal is to imp…

This study looked at two ways of monitoring wet age-related macular degeneration (AMD) using eye scans: standard OCT B-scans and a newer technique called OCT angiography. The goal was to see if the newer scan could better detect when the disease is active, helping doctors decide …

This completed study examined inflammation markers in the fluid from the eyes of 82 people with different stages of age-related macular degeneration (AMD) and a control group without AMD. Researchers collected samples during cataract surgery and tested for 27 inflammation-related…

This completed study observed 572 patients with neovascular age-related macular degeneration or diabetic macular edema who were already receiving brolucizumab injections. Researchers collected routine medical data to see how well the drug resolved fluid in the eye and improved vi…

This study looked at over 550,000 people who received Eylea® injections for eye conditions to find out how often retinal vasculitis (a rare eye inflammation) occurs. Researchers used a large US registry and medical records to confirm cases. The goal was to better understand the s…

This study tested a new, non-invasive eye scan called OCT angiography to see if it can better detect changes in abnormal blood vessels in people with wet age-related macular degeneration (AMD) who are being treated with Eylea. Researchers followed 49 patients to compare the new s…